Clinical Perspective

What is new?
A given magnitude of BP lowering provides similar relative benefit at all levels of CVD risk, but greater absolute benefit (and therefore lower NNT) as risk increases; suggesting that high-risk individuals are more likely to benefit from intensive BP goals (e.g. systolic mmHg, as supported by SPRINT).
To our knowledge, this is the first study to evaluate whether CAC may personalize the risk-based treatment of hypertension.
Added to estimation of CVD risk and discussion of patient treatment preferences, CAC identifies individuals who may benefit from an intensive systolic BP goal of 120 mmHg versus a traditional goal of 140 mmHg.
What are the clinical implications?
Information on CAC burden (particularly when CAC results have already been obtained for other reasons) may be considered when making personalized treatment decisions about blood pressure targets, particularly among persons with estimated cardiovascular disease risk between 5-15% and who have either pre-hypertension or mild hypertension.
A precision medicine clinical trial evaluating risk-based blood pressure treatment goals, preferably incorporating CAC and not just risk-factor based estimations, is desirable.
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Introduction
Elevated blood pressure (BP) is a major cause of heart disease, stroke, and heart failure, with over 972 million adults worldwide and approximately one in three U.S. adults diagnosed with hypertension. 1 While effective antihypertensive pharmacotherapies are widely available, 2 there has been recent controversy regarding the optimal systolic BP (SBP) threshold to initiate or intensify treatment. For example, relying on data from randomized trials (and excluding observational results), a 2014 report by the eighth panel appointed to the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC- 8) found no trial evidence to support initiating therapy until a SBP of 150 mmHg or higher in adults older than 60 who do not have diabetes or chronic kidney disease. 3 This recommendation was controversial 4 and differs from other guidelines and advisories, the majority of which recommend a lower threshold of 140 mmHg.
Furthermore, after JNC-8 was released, the landmark Systolic Blood Pressure Intervention Trial (SPRINT) 5 reported significant improvements in outcomes, notably ASCVD and heart failure, among 9,361 high-risk non-diabetic hypertensive patients, older than 50, treated to a SBP target of 120 mm Hg or less versus the standard target of 140 mmHg or less. Thus, questions remain about whom to treat and with what treatment intensity, particularly among individuals with prehypertension or mild hypertension.
In this context, there has been heightened interest in the use of global ASCVD risk estimates -in conjunction with SBP -to guide initiation and titration treatment decisions for hypertension. [6] [7] [8] [9] This strategy may allow providers to balance the tension between avoiding overtreatment among low risk persons who are unlikely to benefit and intensifying treatment to achieve lower SBP in higher-risk adults. Prior reports of risk-based allocation of BP therapy have diabetes or chronic kidney disease. 3 This recommendation was controversial 4 an an and d d di di d ff ff ffer er rs s fr fr from other guidelines and advisories, the majority of which recommend a lower threshold r of 140 mmHg Furthermore, after JNC-8 was released, the landmark Systolic Blood Pressure Intervention Tria SPR PR PRI IN I T) 5 repo po port ted ed ed s s sig ig gni ni nifi fi f ca a ant nt nt i i imp mp mpro ove v ment t ts s in n o outco co come me mes, s, s, n not ot tab ab ably ly AS A CV CV CVD D D an an and he he h ar ar art t t fa fa fail il ilure amon on ong 9,361 hi hi high gh g -r risk k non n n-d di d abetic hyp ypertens s si ive p pati ti tien en ents ts ts, ol older th han 5 50, t tr t eated to to t a a S SBP ta ar rge of 120 mm Hg H or l less versus the standard target of 140 mmHg H or less. Th hus, questions remain by guest on December 13, 2016 http://circ.ahajournals.org/ Downloaded from focused exclusively on risk estimates derived from traditional clinical risk factors such as those included in the ACC/AHA 2013 ASCVD risk score. 6, 8, 10, 11 Coronary Artery Calcium (CAC), measured by non-contrast cardiac CT, is a powerful subclinical marker of absolute and relative ASCVD risk and has been demonstrated to add incremental prognostic information to risk estimates derived from traditional risk factors. [12] [13] [14] In addition, prior analyses have suggested that CAC testing has potential to personalize allocation of other preventive therapies (e.g., aspirin or statin) by identifying individuals who are unlikely to obtain net benefit (e.g., those with zero CAC generally have very low absolute ten-year risk and, hence, high estimated number-needed-to-treat [NNT]), as well as those who may be more likely to benefit due to high absolute risk (e.g., CAC>100). 15, 16 Therefore, in this study we sought to determine whether CAC might inform the identification of primary prevention candidates who are more likely to benefit from initiation or titration of antihypertensive therapy to a more intensive SBP goal of 120 mmHg (compared to the current standard of 140 mmHg).
Methods
Study Participants
MESA is a multi-center, multi-ethnic, prospective observational cohort study. 17 o benefit due to high absolute risk (e.g., CAC>100). 15, 16 Therefore, in this study we sought to determine whether CAC might inform the dentification of primary prevention candidates who are more likely to benefit from initiation o itra atio i ion of ant ti i ih hy h pe pe perten en e si si sive ve v t the he hera ra rapy py py to a a more in in inte en nsiv ve e e SB SB failure, one or more additional factors, such as pulmonary edema by X-ray, poor left ventricular systolic function, or diastolic dysfunction, were also required. Participants who suffered both CVD and heart failure were censored from this analysis after the first event.
Statistical Analysis
In order to examine the potential implications of CAC testing for both intensification (e.g. titration)
and initiation of BP therapy to a more intensive SBP goal, we included persons with and without baseline anti-hypertensive medication use ( failure, one or more additional factors, such as pulmonary edema by X-ray, poor left ventricula ystolic function, or diastolic dysfunction, were also required. Participants who suffered both CVD and d he h heart failur ur re e e we we were e c c cen en enso sore e ed d d fr fr from om om th his i analys ys y is a after er r t t the he he f f fir ir i st t e e eve ve vent n .
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n order to examine the potential implications of f CA AC testing for both intensifi ficati ion (e.g. titration by guest on December 13, 2016 http://circ.ahajournals.org/ Downloaded from personalize risk assessment among subgroups of varying SBP and ASCVD risk estimates, these BP categories were further stratified on the basis of, first, ten-year ASCVD risk (<15% or 15% 5, 6 , 20 which was the median level of risk in our primary sample) and, second, CAC group (0, 1-100, >100). We compared crude event (incidence) rates, as well as Cox multivariable-adjusted hazard ratios, within each of these CAC strata.
Models were adjusted for age, sex, race/ethnicity category, BMI, fasting-glucose, diabetes status (yes/no), creatinine, smoking category, LDL-C, HDL-C, triglycerides, statin use, and family history of myocardial infarction (yes/no). In models where the sample was stratified by core demographics and variables not included in the ASCVD equation (BMI, creatinine, triglycerides, statin use, and family history of myocardial infarction). We conducted sensitivity analyses with more parsimonious models adjusted just for, 1) demographics alone (age, sex, and race/ethnicity), and 2) using the 13 variables included in the primary model, we constructed a propensity score for the composite outcome within each of the CAC subgroups and adjusted the model for this score as a single variable.
We estimated a 10-year number needed to treat to prevent the primary outcome of allcause CVD or HF (NNT10) with treatment initiation or intensification to a systolic goal of 120 mmHg. This was calculated by applying the expected relative risk reduction derived either from meta-analysis (22% reduction in CHD, 41% reduction in stroke and 24% reduction in heart failure for each 10 mmHg lowering of systolic BP 21 ) in the primary sample, or directly from SPRINT (25% relative reduction for a target of 120 mmHg versus a target of 140 mmHg 5 ) in the secondary analysis of the SPRINT-eligible subsample. The NNT10 was calculated directly as the reciprocal of the absolute risk difference at the median follow-up of the cohort on the basis of Kaplan-Meier estimates and was subsequently adjusted to a NNT10 according to the Altman-Anderson method. 22 ASCVD equation (BMI, creatinine, triglycerides, statin use, and family history y of of of m m myo yo yoca ca card rd rdia nfarction). We conducted sensitivity analyses with more parsimonious models adjusted just for 1) demog graphics alone (age, sex, and race/ethnicity), and 2) using the 13 variables included in the prim ma a ary model l, l w w we e co o ons ns str tr truc u te te ed d d a a a pr pr propen ensity s s sco c re e for r t t the he he c c com om o po po osi si s te te o out u co ome me me w w wit it ithin n n ea ea ach ch ch o o of f f the CA A AC C C subgroup p ps s s an nd d ad adj justed ed ed the mode el for thi hi is s sc co ore e e as as as a a sin i ing gle v variab bl le. .
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In a sensitivity analysis, using the same statistical techniques, we modeled NNT10 for a systolic goal of 130 mmHg. We also conducted a sensitivity analysis of NNT10 for a goal of 120mmHg that included lower cut-points of 10-year estimated ASCVD risk (<5% or <10%). Finally, we estimated NNT10 for a goal of 120mmHg to prevent each of the individual endpoints included in the main composite (CHD, stroke, and heart failure) and we also conducted analyses in the diabetic-subgroup of our primary MESA sample.
Results
Baseline characteristics of the primary sample and of the SPRINT-eligible subsample, stratified by anti-hypertensive medication use, are shown in Table 1 . Except for a lower proportion of males and being less likely to smoke, persons receiving BP therapy at baseline were older and had a higher burden of ASCVD risk factors than those who were not on BP therapy at baseline. Those receiving BP therapy also had higher SBP than those not on therapy. Diastolic BP levels, while clinically similar (75.6 vs. 76.2 mmHg), were statistically lower among those on BP therapy. The distribution of CAC also differed according to baseline BP treatment status ( Figure 1 ).
Over a median (interquartile range) follow-up of 10.2 (9.7-10.7) years, 642 primary composite outcome events (all-cause CVD or heart failure) occurred in the sample overall. Figure   2 demonstrates that cumulative event-free survival was significantly lower, in both the primary sample and SPRINT-eligible subsample, among individuals with CAC 1-100 and >100, compared to those with zero CAC. Similar trends were demonstrated after stratification by baseline systolic BP category (eFigure 1). These trends were also qualitatively similar for the individual outcomes of CHD, stroke, and heart failure (eFigure 2).
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Adjusted Cox models confirmed that, relative to CAC=0, CAC 1-100 and CAC >100 carried incremental excess in hazard for events among persons with SBP in the 120-139 mmHg and 140-159 mmHg ranges, irrespective of baseline treatment status (Table 2 ). However, associations between CAC and hazard for events among those with SBP 160-179 mmHg were not statistically significant, either with or without baseline therapy. All of these trends were qualitatively similar in the SPRINT-eligible subsample. Adjusted Cox models confirmed that, relative to CAC=0, CAC 1-100 and CAC >100 Adjusted Cox models demonstrated increased hazard for events with CAC 1-100 and CAC >100 (versus CAC=0) among those who had SBP levels in the range of 120-139 mmHg and 140-159 mmHg, but, no statistical association of CAC with CVD among those with SBP 160-179 mmHg ( Table 3 ). Excess relative hazard with increasing CAC strata was most pronounced in those with estimated ASCVD risk <15%. Parsimonious demographic-adjusted and propensity scoreadjusted models produced similar results (eTables 1-4). As in Table 2 , all of these trends were qualitatively similar in the SPRINT-eligible subsample. None of the hazard ratios presented in Table 3 demonstrated any interaction by race/ethnicity.
The absolute differences in event rates according to baseline CAC translated into substantial variation in estimated NNT10 to prevent all-cause CVD or heart failure with BP lowering to a SBP goal of 120 mmHg. For example, a low NNT10 (between 4 and 8), was estimated for persons with CAC >100 in both the SBP 140-159 and 160-179 mmHg categories, irrespective of baseline estimated ASCVD risk (Table 4 ). In contrast, participants with CAC=0 had higher estimated NNT10 at all levels of baseline SBP and ASCVD risk. Persons with SBP <140 mmHg, ASCVD risk <15% and zero CAC had the highest NNT10 estimates (NNT10= 99). Likely due to the higher baseline SBP and ASCVD risk in those who were SPRINT eligible, with higher consequent event rates, all NNT10 levels were relatively low in this sub-sample. The NNT10 results were qualitatively similar when the sample overall was stratified by baseline treatment status (as such, NNT10 for a goal SBP of 120 mmHg was similar for both initiation of BP therapy and intensification of prior therapy, eTable 5). Because CAC stratifies absolute risk for CHD, stroke, Table 3 with findings most widely dispersed among those with ASCVD risk <15% and who had either prehypertension or mild hypertension. In addition, sensitivity analyses evaluating lower ASCVD risk cut-points suggested that, among participants with SBP 120-139 mmHg, 32% of persons with ASCVD risk <7.5% had CAC>0 (with NNT10 estimates for a 120 mmHg SBP goal of 76 for CAC1-100 and 47 for CAC>100), whereas CAC>0 was less frequent and NNT10 estimates were higher among those with ASCVD risk <5% (e.g., NNT10 estimates for a 120 mmHg SBP goal of 180 for the 20% with CAC 1-100 and 37 for the 3% with CAC>100) (eTable 7).
The exploratory analysis of diabetics in our sample suggested that NNT10 estimates were low, irrespective of CAC, among those with 10sample had ASCVD risk <15% to judge whether CAC has any role in guiding risk-based BP therapy in this setting (eTable 8). Finally, eTable 9 demonstrates our NNT10 estimates from the sensitivity analysis evaluating a SBP goal of 130mmHg. As expected, NNT10 estimates were higher (i.e., less benefit) when targeting 130 mmHg compared to 120 mmHg systolic, particularly among those at highest risk due to elevated baseline CAC.
Discussion
Our results add to an emerging body of literature suggesting that ASCVD risk may be useful in defining more personalized BP goals and could guide a precision medicine approach for both initiation and intensification of anti-hypertensive treatment. First, CAC was a powerful determinant of absolute risk for the composite of all-cause CVD or heart failure. Second, persons 180 for the 20% with CAC 1-100 and 37 for the 3% with CAC>100) (eTable 7).
The exploratory analysis of diabetics in our sample suggested that NNT10 estimates were ow, irrespe p ctive of CAC, among those with 10amp mp mpl l le had A A ASC SC SCVD VD VD r ris is isk k k <1 <1 < 5% 5% 5% with zero CAC in both the prehypertension (120-139 mm Hg) and mild hypertension (140-159 mmHg) SBP categories had low ten-year event rates (e.g., <7.5 per 1,000 person-years). This was particularly true for those not already on BP therapy at baseline in whom the decision to initiate treatment may be under consideration, but also applied to persons on baseline therapy in whom intensification of treatment may be considered. All participants with SBP >160 mmHg had high event rates, irrespective of CAC levels.
Third, CAC may be most suitable for guiding therapeutic decisions (specifically, either initiation or intensification to a more intensive systolic goal of 120 mmHg) when both SBP is between 120-159 mmHg and ten-year ASCVD has been estimated as <15%. In these individuals, CAC=0 yielded a higher estimated NNT for persons with SBP 140-159 (NNT10= 36), and, above all, for those with SBP between 120 and 139 mmHg (NNT10= 99), suggesting lower likelihood for benefit. The latter group consists of those in whom the decision to treat to a more intensive goal of 120 mmHg (compared to the traditional goal of 140 mmHg) may be most challenging in the context of results from SPRINT. Given that 97% of MESA participants with estimated ASCVD risk <5% have CAC <100 and NNT10 estimates ranging from 180-273, our sensitivity analyses suggest that CAC may be most practical for this purpose when SBP is between 120 and 159 mmHg and estimated ASCVD risk is between 5 and 15%.
The above inferences are most appropriately applied to general community intermediate to low risk populations similar to MESA. Our secondary analysis results suggest that the relatively few adults fulfilling strict SPRINT eligibility criteria (just 7.6% of the overall U.S. population 23 ) are, by definition, high risk for CVD or heart failure and the further use of CAC imaging in these individuals may be less helpful in deciding SBP goals. The traditional paradigm of allocating BP therapy solely on BP values makes intuitive and physiological sense. However, data have consistently demonstrated that, while the relative risk reduction in events per unit of SBP lowering is the same, the absolute risk reduction, NNT, and, hence, clinical efficacy of BP treatment increases as baseline absolute ASCVD risk increases. 8 In fact, the idea of using baseline ASCVD risk to guide BP therapy is not new. 24, 25 Moreover, the concept of using risk to allocate ASCVD prevention therapies has taken center stage after the release of 2013 ACC/AHA guidelines for the treatment of cholesterol in adults, which recommend statins be considered based on an ASCVD risk of solely on LDL-C values. 26 Indeed, recent data from the Heart Outcomes Prevention Evaluation (HOPE)-3 trial support the Presumably BP values will always be important in allocating antihypertensive therapy and our data support this. Specifically, participants in our analysis with SBP >160 mmHg, had otherwise not typically considered to benefit from treatment initiation or intensification (e.g. those with SBP 120-139 mmHg). 6 For example, Karmali et al. found that most excess ASCVD events occur in persons with BP levels considered at goal by JNC-8 and that the vast majority of those who suffer these events have elevated ASCVD risk. 11 Estimating risk based on traditional risk factors alone can be misleading 28 and CAC has been repeatedly shown to improve the accuracy of risk assessment. 29, 30 Furthermore, we have previously shown that CAC may inform NNT estimation for other ASCVD prevention therapies. 15, 16 In addition, CAC and intensive BP control such as that used in SPRINT both have supportive evidence for cost-effectiveness. 31, 32 As such, our data could extend the utility of CAC to guiding risk-based determination of more personalized systolic BP goals in persons with mild hypertension and pre-hypertension. This may be relevant for deciding whether to refer for CAC-imaging but is particularly meaningful for those who have already had CAC testing for other reasons.
Importantly, our analyses incorporate clinically relevant information on both baseline BP and estimated ASCVD risk into the calculation of CAC-based NNT estimates. This is crucial as we believe that CAC should not be used in isolation in this context. Specifically, as long as ASCVD risk is <15% and SBP is between 120-159 mmHg, our results suggest the potential for CAC=0 to allow more liberal BP treatment goals, like 140 mmHg for example, particularly if based on individual patient preferences. 33 Indeed, CAC may be most helpful in cases where physicians are considering intensifying treatment to a SPRINT-based SBP goal of <120 mm Hg among persons with SBP between 120-139 mmHg (i.e. levels below the current traditional goal of 140 mmHg). In this setting, when ASCVD risk is <15%, a CAC=0 yields a NNT10 of approximately 100, information which could guide the clinical-patient treatment discussion. Of evidence for cost-effectiveness. 31, 32 As such, our data could extend the utility of f CA CA AC C C to to to g g gui ui uidi d d ng
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when CAC>100 among those individuals currently in the therapeutic 'grey zone' (i.e., those with SBP in the prehypertension and mild hypertension range and who are intermediate risk by CVD risk scores).
Our analysis has some limitations. While we believe that our findings may have important clinical implications and can guide future investigation, they are hypothesis-generating due to the observational nature of the data and the limited numbers of events among certain subgroups. The latter consideration is most relevant among those with SBP 160-179 mmHg and for our SPRINT-eligible subsample. Our NNT estimates are based on a number of assumptions (in particular that the relative risk reduction for BP therapy is similar among CAC strata), nonetheless, we feel they are informative. While some have argued that SPRINT SBP values cannot easily be translated into routine care 34 , we note that the MESA BP measurement protocol was nearly identical to SPRINT and that MESA also used automated oscillometric BP measurement devices.
Because MESA was not designed to capture accurate time-to-event data on side effects of antihypertensive medication (e.g. electrolyte imbalance or injurious falls), we do not have absolute event rates for these outcomes among CAC strata and are unable to generate number-needed-to-SBP in the prehypertension and mild hypertension range and who are intermediat ate e e ri ri risk sk k b b by y y CV CV CVD isk scores).
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Conclusions
Assessment of CAC may inform more personalized BP goals (e.g., choosing between a traditional SBP goal of 140 mmHg or a more intensive goal of 120 mmHg), particularly among persons with baseline ten-year ASCVD risk estimates between 5-15% and who have systolic BP levels between 120-159 mmHg. Specifically, among these individuals, CAC >100 appears to identify those who would likely benefit from an intensive systolic BP goal of 120 mmHg, whereas CAC=0 identifies individuals who may be suitable for more traditional SBP goals; thereby avoiding unnecessary intensification of medication and instead focusing on healthy lifestyle measures. A trial of riskbased allocation of BP treatment goals, preferably incorporating CAC, is needed.
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